10:16:32 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-27 Bokslutskommuniké 2024
2024-11-28 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-05-30 Kvartalsrapport 2024-Q1
2024-03-20 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-11-29 Kvartalsrapport 2023-Q3
2023-08-30 Kvartalsrapport 2023-Q2
2023-05-31 Kvartalsrapport 2023-Q1
2023-03-22 Ordinarie utdelning FLUO 0.00 DKK
2023-03-21 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-31 Kvartalsrapport 2022-Q1
2022-05-19 Ordinarie utdelning FLUO 0.00 DKK
2022-05-18 Årsstämma 2022
2022-03-30 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-05-03 Ordinarie utdelning FLUO 0.00 DKK
2021-02-26 Bokslutskommuniké 2020
2021-02-09 Årsstämma 2021
2020-11-20 Kvartalsrapport 2020-Q3
2020-08-14 Kvartalsrapport 2020-Q2
2020-05-27 Kvartalsrapport 2020-Q1
2020-04-09 Ordinarie utdelning FLUO 0.00 DKK
2020-04-08 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-29 Kvartalsrapport 2019-Q3
2019-05-31 Kvartalsrapport 2019-Q1

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
FluoGuide är ett danskt bolag verksamma inom medicinteknik. Bolaget affärsfokus återfinns inom forskning och utveckling av behandlingar mot olika cancerformer, med störst fokus på utveckling av produkter som vägleder vid kirurgiska ingrepp. Produkterna binder till sig cancercellerna som då lyser upp och är avsedda att användas för att med precision kunna ta bort skadliga tumörer i patientens vävnad.
2023-08-28 12:53:00

Copenhagen, Denmark, 28 August 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the issue of 211,389 warrants to the investors participating in the directed share issue conducted on the 7 July 2023 has been completed.

Today, the Board of Directors of FluoGuide has exercised its authorization to issue new warrants by issuing in aggregate 211,389 warrants to the investors participating in the directed rights issue. All warrants are issued free of change.
The warrants are issued in accordance with FluoGuide’s authorization in Clause 3.5.1-3.5.3 of the Articles of Association as adopted by the shareholders acting in general meeting.

Each warrant confers the right to subscribe nominal DKK 0.1 share in the company at a subscription price corresponding to 85% VWAP of the company’s shares in the period 10-24 November 2023, however no less than SEK 50 per share or above 120 SEK per share. The warrants may be exercised in the period 27 November to 1 December 2023. The warrants will not be listed for trading. Warrants that are not exercised during the exercise period will lapse without compensation to the warrant holders. Apart from the terms listed above the warrants will upon issuance contain customary provisions regarding adjustments in connection with capital changes in the Company as well as provisions concerning specific events such as merger etc.

The warrants represent a total dilution of 1.8% of the current share capital, if vested and exercised.

The detailed terms of all warrants issued by the Company can be found in the Articles of Association on the Company’s website under https://fluoguide.com/investor/compliance/, following registration with the Danish Business Authorities.

For further information, please contact:
Morten Albrechtsen, CEO
FluoGuide A/S
+45 24 25 62 66
ma@fluoguide.com
 
Certified Adviser:
Svensk Kapitalmarknadsgransking AB
Phone: +46 70 755 95 51
E-mail: ca@skmg.se

About FluoGuide
FluoGuide takes precision surgery to the next level improving the outcome for cancer patients. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. This improved precision enabled by FluoGuide’s products is expected to have a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, this improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company has demonstrated efficacy of FG001 as well as it being well tolerated and safe in the completed proof-of-concept clinical study (phase I/IIa) in patients with aggressive brain cancer (high grade glioma) that undergo surgery. A phase IIb trial in aggressive brain cancer is ongoing to obtain valuable information to design the phase III trial. In addition, FluoGuide has demonstrated effect of FG001 in lung and head & neck cancer, topline, and positive interim result, respectively. A trial in meningioma and glioma is commencing.

FluoGuide is listed on Nasdaq First North Growth Market, Stockholm under the ticker “FLUO”.

Read more about FluoGuides pipeline, technology, and upcoming events on www.fluoguide.com